%0 Journal Article %A Liangjiang Huang %A Qian Li %A Sayed Zulfiqar Ali Shah %A Mohammad Nasb %A Chen Bin %A Iftikhar Ali %A Lingfeng Xie %A Jifa Hu %A Hong Chen %T Ultra-short-wave diathermy shortens the course of moderate and severe COVID-19: a randomized controlled trial %D 2021 %R 10.1101/2021.01.28.21250163 %J medRxiv %P 2021.01.28.21250163 %X Background COVID-19 patients have severe lung injury. The USWD could play a supportive role in relieving lung injury and enhance clinical recovery.Methods and findings The design was a single-center, evaluator blinded; 2-arm parallel design superiority randomized controlled clinical trial. Moderate and severe coronavirus-2 (SARS-CoV-2) positive patients with acute respiratory syndrome, Fifty patients were randomized (USWD, 25; control, 25) between February 18/2020 and April 20/2020. There were male 22 (44.0%) and female 28 (56.0%) with mean (SD) age 53(10.69). Time to clinical recovery (USWD 36.84 vs control 43.56, P = 0.03) was significantly shortened with a between-group difference of 6.72 days. The median SIRS score at day 28 was 0 (0-1) in the USWD group, while 0 (0-2) in the control group (P = 0.011), and the seven-point scale at day 28 showed significant improvement in the USWD group (P = 0.003). While the rate of RNA negative conversion at day 7 (2/25 vs 7/25, p=0.054), day 14 (14/25 vs 18/25 p=0.239), day 21 (22/25 vs 18/25 p=0.279), and day 28 (25/25 vs 22/25 p=0.730) did not show statistical significance. Similarly, no significant differences were observed in the AI-assisted CT analysis. No treatment-associated adverse events or worsening of pulmonary fibrosis were found.Conclusions Among the 50 moderate and severe COVID-19 patients, the USWD as an adjunctive therapy to standard therapy could shorten the recovery course and enhance clinical improvement without aggravating pulmonary fibrosis. However, the study did not report statistical significance in the negative conversion rates of SARS-CoV-2 nucleic acid due to the small sample size and early termination, the findings of this study are limited.TRIAL REGISTRATION Chinese Clinical Trial Registry: ChiCTR2000029972, URL: http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000029972Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000029972Funding StatementThe study was funded by the National Key Research and Development program(NO:2020YFC08845600).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:this randomized controlled trial was approved by the ethics committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (certificate of approval number TJ-C20200127)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe trial data could be provided by a reasonable request to the corresponding authors (HC). http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000029972 %U https://www.medrxiv.org/content/medrxiv/early/2021/02/01/2021.01.28.21250163.full.pdf